Equillium (EQ) EBIT Margin (2023 - 2024)
Equillium (EQ) posted quarterly EBIT Margin of 106.97% for Q4 2024, down 7223.0% year-over-year from 1.5% in Q1 2024, and down 1815.8% quarter-over-quarter from 5.58% in Q3 2024.
Powered by 
Analysis
Equillium (EQ) EBIT Margin (2023 - 2024) Analysis & Trends
Equillium (EQ) has reported EBIT Margin for 2 consecutive years, with 106.97% the latest figure, recorded in Q4 2024.
- In Q4 2024, EBIT Margin fell 7223.0% year-over-year to 106.97%; the TTM figure through Sep 2025 stood at 554.9% (down 54015.0% YoY), while the FY2024 annual figure was 20.12%, up 2012.0% from the prior year.
- EBIT Margin slipped to 106.97% in Q4 2024 per EQ's latest filing, from 5.58% in the prior quarter.
- Across five years, EBIT Margin topped out at 0.72% in Q2 2024 and bottomed at 106.97% in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -106.97% |
| Sep 30, 2024 | -5.58% |
| Jun 30, 2024 | -0.72% |
| Mar 31, 2024 | -26.11% |
| Dec 31, 2023 | -34.74% |
| Sep 30, 2023 | -40.85% |
| Jun 30, 2023 | -39.36% |
| Mar 31, 2023 | -46.27% |